Pfizer (Switzerland)

Recent papers from Pfizer (Switzerland)

1. Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05Future Oncology · 2026
2. Best-practice recommendations for the transition care pathway for children and young people with moderate to severe ulcerative colitis: a modified Delphi panel with UK health care professionalsFrontline Gastroenterology · 2026
3. Bowel Urgency in Ulcerative Colitis Is Associated With Clinical Endpoints, Health-Related Quality of Life, and Biomarkers: Data From the Etrasimod ELEVATE UC 52 TrialCrohn s & Colitis 360 · 2026
4. The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical programTherapeutic Advances in Gastroenterology · 2026
5. Empirical estimate for the indirect healthcare costs of sickle cell disease from a retrospective cohort study in England between 2007 and 2019BMC Health Services Research · 2026
6. The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR TrialClinical Gastroenterology and Hepatology · 2026
7. SigVie-003: Phase 3 trial of frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab alone in non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥50%.Journal of Clinical Oncology · 2026
8. 423RO Addition of tucatinib to trastuzumab emtansine (T-DM1) in patients with previously treated HER2+ locally advanced/metastatic breast cancer (LA/MBC): Updated efficacy analysis from the HER2CLIMB-02 trialESMO Open · 2026
9. Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC programInflammatory Bowel Diseases · 2025
10. Direct healthcare costs associated with sickle cell disease complications: a retrospective cohort study using routinely collected healthcare data in EnglandBMJ Open · 2026
11. International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-RORJournal of Clinical Oncology · 2026
12. DOP062Efficacy of etrasimod in biologic/Janus kinase inhibitor-naïve patients with mildly to moderately active Ulcerative Colitis: results from the GLADIATOR trialJournal of Crohn s and Colitis · 2026
13. P0593Impact of up to 3 years of continuous etrasimod treatment: Long-term efficacy results from the ELEVATE UC open-label extensionJournal of Crohn s and Colitis · 2026
14. DOP063Etrasimod efficacy in patients with mildly to moderately active Ulcerative Colitis: pooled results from the ELEVATE UC and GLADIATOR trialsJournal of Crohn s and Colitis · 2026
15. P1075Etrasimod for the treatment of Ulcerative Colitis: up to 5 years of safety data from the global clinical programmeJournal of Crohn s and Colitis · 2026
16. P0924Long-term etrasimod efficacy in patients with Ulcerative Colitis stratified by prior biologic/JAKi experience: 2-year outcomes from ELEVATE UC OLEJournal of Crohn s and Colitis · 2026
17. Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020American Journal of Hematology · 2025
18. Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study designFuture Oncology · 2025
19. HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast CancerJournal of Clinical Oncology · 2025
20. Seroprevalence of Borrelia burgdorferi sensu lato and incidence of Lyme borreliosis in SwitzerlandTicks and Tick-borne Diseases · 2025